multiple sclerosis

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

Roche chief medical officer Levi Garraway

Roche's oral MS hope fenebrutinib hits the mark in phase 3

Roche's oral BTK inhibitor fenebrutinib is on track for filings next year for multiple sclerosis after clearing two phase 3 trials.

News

Roche builds case for MS drug with two-year efficacy data

Roche has revealed good results from a phase 2 trial of its oral BTK drug fenebrutinib in relapsing multiple sclerosis as it waits for phase 3 data.

News

FDA starts review of Sanofi's MS hope tolebrutinib

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis.

News

Merck MS tablet set for wider use by NHS in England

Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad.

News

Teva fined €462.6m for antitrust delay to MS drug rivals

The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copax

Sandoz launches first biosimilar Tysabri in US

Roche's oral MS hope fenebrutinib hits the mark in phase 3

Roche builds case for MS drug with two-year efficacy data

FDA starts review of Sanofi's MS hope tolebrutinib

Merck MS tablet set for wider use by NHS in England

Teva fined €462.6m for antitrust delay to MS drug rivals

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

multiple sclerosis

Editor's Picks